Your A-Z of episodes

Did you know there’s even more we can do to promote your episode? Find out more…

  • Episode 194

    Meet the Top Gun CDMO Maverick

    John Fowler

    / Pii (Pharmaceutics International, Inc.)

    John Fowler, CEO at Pii, joins the podcast to share insights on the skills needed to lead a successful CDMO in today’s challenging market.

  • Episode 193

    Pfizer’s retired manufacturing veteran

    Peter Stevenson

    / Independent Director and Pharma industry veteran

    Pharma industry veteran Peter Stevenson joins the podcast to share insights from his experience leading Pfizer’s CDMO, Pfizer CentreOne.

  • Episode 192

    Tasty Topics: Navigating Novo Nordisk’s Acquisition of Catalent

    Dirk Lange, Brett Alderson, John Cameron & Janet Hoogstraate

    / Pyramid Labs, NovaCina, Corden Pharma & NorthX Biologics

    Hear sector experts discuss the potential impacts of Novo’s acquisition of Catalent and maximizing GLP-1 manufacturing capacity.

  • Episode 191

    Reimagining drug development

    Jen Nwankwo

    / 1910 Genetics

    Jen Nwankwo, Founder and CEO of 1910 Genetics, recently joined the podcast to discuss how 1910 is reshaping the industry and drug discovery.

  • Episode 190

    A lifetime of drug hunting

    Karen Lackey

    / X-Chem

    Karen Lackey, CEO at X-Chem recently discussed why she moved away from Big Pharma after 30 years to move to a global CRO.

  • Episode 189

    The pink-haired CEO

    Emma Banks

    / ramarketing

    Emma Banks, CEO at ramarketing, joined the podcast and spoke on how, despite market headwinds, the pharma services sector is looking up.

  • Episode 188

    The Harvard spin-out disrupting drug discovery

    Rani Powers

    / Pluto Bio

    Rani Powers, Founder & CEO of Pluto Bio, shares how her passion for coding and biology led to Pluto, a platform accelerating drug discovery.

  • Episode 187

    The rare disease champion

    Tamar Thompson

    / Alexion, AstraZeneca Rare Disease

    Tamar Thompson Head of Global Corporate Affairs at Alexion, AstraZeneca Rare Disease, joins the podcast to discuss the value and impact being acquired by AstraZeneca had on Alexion

  • Episode 186

    The VC Biotech investor

    Chris Garabedian

    / Xontogeny

    In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Chris Garabedian, CEO at Xontogeny and Venture Fund Manager at Perceptive Advisors. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Chris, covering: Chris Garabedian founded Xontogeny in June of 2016 to

  • Episode 185

    The diamond in the rough

    Kent Payne

    / Aliri Bioanalysis

    Kent Payne, CEO at Aliri discusses the value of scientists engaging with clients to build relationships and showcase technical expertise.

  • Load more